From the publishers of JADPRO

MPN Resource Center


Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) project

Last Updated: Wednesday, August 2, 2023

Using electronic health record data from over 80,000 patients with polycythemia vera who were treated with hydroxyurea (HU) only or switched from HU to ruxolitinib, researchers found that the annualized incidence rates (per 100 patients) for HU-only patients decreased from 8.7 before HU to 5.6 during HU but increased to 10.5 when continuing HU. In comparison, incidence rates decreased from 10.8 before HU to 8.4 during HU and was maintained at 8.3 after switching to ruxolitinib. They also used a machine-learning model to identify lymphocyte percentage, neutrophil percentage, and red cell distribution width as key markers of thromboembolic event risk among this patient population. 

News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia


Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study